Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
stocks
AI isn’t an economic moat killer, but it will disrupt industries
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,726.50 | 32.00 | -0.37% |
| CAC 40 | 7,774.64 | 71.91 | -0.92% |
| DAX 40 | 22,612.54 | 344.54 | -1.50% |
| Dow JONES (US) | 46,210.09 | 219.40 | -0.47% |
| FTSE 100 | 9,971.65 | 135.19 | -1.34% |
| HKSE | 24,856.43 | 479.52 | -1.89% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 53,603.65 | 145.97 | -0.27% |
| NZX 50 Index | 12,976.99 | 47.69 | 0.37% |
| S&P 500 | 6,540.41 | 51.49 | -0.78% |
| S&P/ASX 200 | 8,525.70 | 21.30 | -0.25% |
| SSE Composite Index | 3,889.08 | 42.75 | -1.09% |